Archive: 01/08/2017
Idhifa approved for some with acute myeloid leukemia
(HealthDay)—Idhifa (enasidenib) has been approved by the U.S. Food and Drug Administration to treat adults with a specific genetic mutation that leads to relapsed or refractory acute myeloid leukemia (AML).
Aug 1, 2017